Clinical Trials Logo

Preeclampsia Postpartum clinical trials

View clinical trials related to Preeclampsia Postpartum.

Filter by:

NCT ID: NCT06373367 Not yet recruiting - Preeclampsia Clinical Trials

Preeclampsia Educational Program Study (PrEPS)

PrEPS
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.

NCT ID: NCT06353256 Not yet recruiting - Clinical trials for Preeclampsia Postpartum

A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes

AW2H
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

United States maternal mortality and preterm birth rates are among the highest among high-income countries due in part to a combination of racial, regional and socioeconomic disparities in access to care and overall health. The research proposed focuses on adapting and expanding a perinatal community health worker intervention for Black postpartum patients with preeclampsia (PE) and other adverse pregnancy outcomes (APOs). Investigators will partner with a community-based organization that trains and deploys community health workers. Investigators will test an intervention for urban and rural Black postpartum patients with APOs to 1) enhance blood pressure control postpartum and 2) promote long-term cardiovascular disease prevention for this underserved population. This pilot study will determine if randomizing and implementing a community health worker intervention tailored to pregnant people experiencing preeclampsia is feasible and found to be acceptable by participants.

NCT ID: NCT05937841 Recruiting - Clinical trials for Preeclampsia Postpartum

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Start date: June 28, 2023
Phase: Early Phase 1
Study type: Interventional

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

NCT ID: NCT05924971 Recruiting - Clinical trials for Preeclampsia Postpartum

Aspirin for Postpartum Patients With Preeclampsia

ASAPP
Start date: July 26, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

NCT ID: NCT05534932 Recruiting - Clinical trials for Preeclampsia Postpartum

Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

GDMT For PE
Start date: October 27, 2022
Phase: N/A
Study type: Interventional

This is a single-center, open-label pilot study looking at how Guideline-directed management and therapy (GDMP) in post-partum women with preeclampsia can improve Global Longitudinal Strain (GLS).

NCT ID: NCT04632589 Recruiting - Clinical trials for Preeclampsia Postpartum

Losartan for Improved Vascular Endothelial Function After Preeclampsia

LIVE-PE
Start date: November 22, 2020
Phase: Early Phase 1
Study type: Interventional

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage and to test whether taking a medication that blocks angiotensin II receptors (losartan) decrease these negative effects in women who have had preeclampsia. Identification of these mechanisms and treatment strategies may lead to better clinical management,of cardiovascular disease risk in these women. In this study we use the blood vessels in the skin as a representative vascular bed. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickle-sized area of the skin in women who have had preeclampsia. We make these measurements after the subjects take a placebo and after they take losartan (an angiotensin II receptor blocker) to test whether this treatment improves vascular function in these women. As a compliment to these measurements, we also draw blood from the subjects and isolate the inflammatory cells to test how sensitive their inflammatory responses are following the placebo and the losartan treatment.

NCT ID: NCT04479072 Recruiting - Clinical trials for Preeclampsia Postpartum

Aspirin and Preeclampsia

Start date: February 15, 2021
Phase: Phase 4
Study type: Interventional

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

NCT ID: NCT03978767 Recruiting - Preeclampsia Severe Clinical Trials

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

PANDA
Start date: June 10, 2019
Phase: Phase 2
Study type: Interventional

A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.

NCT ID: NCT03667326 Recruiting - Clinical trials for Preeclampsia Postpartum

Postpartum Low-Dose Aspirin and Preeclampsia

Start date: July 22, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

NCT ID: NCT03451266 Completed - Preeclampsia Severe Clinical Trials

Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia

Start date: April 7, 2018
Phase: Phase 1
Study type: Interventional

The objective of the study is to determine whether administration of vitamin C (1.5g/6 hours) in the first three days post-partum reduces the amount of extravascular lung water assessed by lung ultrasound in patients with severe preeclampsia.